Merck's Keytruda meets OS, PFS endpoints in first-line NSCLC

Merck & Co. Inc. (NYSE:MRK) said Keytruda pembrolizumab (MK-3475) met the co-primary endpoints in the Phase III KEYNOTE-189 trial as first-line treatment of metastatic non-squamous non-small cell lung cancer (NSCLC).

An interim analysis of the 614-patient trial by an IDMC

Read the full 396 word article

User Sign In